<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">SHINGYOJI, MASATO</style></author><author><style face="normal" font="default" size="100%">ANDO, SOICHIRO</style></author><author><style face="normal" font="default" size="100%">NISHIMURA, HIROKI</style></author><author><style face="normal" font="default" size="100%">NAKAJIMA, TAKAHIRO</style></author><author><style face="normal" font="default" size="100%">ISHIKAWA, AKI</style></author><author><style face="normal" font="default" size="100%">ITAKURA, MEIJI</style></author><author><style face="normal" font="default" size="100%">IIZASA, TOSHIHIKO</style></author><author><style face="normal" font="default" size="100%">KIMURA, HIDEKI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2635-2639</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><issue><style face="normal" font="default" size="100%">7</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor related to tumor growth and metastasis. However, little is known about the clinical significance of circulating VEGF in cancer patients. Patients and Methods: Eighteen patients with non-small cell lung cancer received chemotherapy using carboplatin and paclitaxel. Plasma levels of VEGF were analyzed at baseline and after 2 cycles of chemotherapy. Results: Partial remission was observed in 3 patients (16.7%), stable disease in 10 patients (55.6%) and progressive disease in 5 patients (27.8%). Patients with partial remission or stable disease had significantly lower levels of plasma VEGF than did patients with progressive disease, both at baseline (p=0.0341) and after 2 cycles of chemotherapy (p=0.0265). There were no significant changes of plasma VEGF during chemotherapy. Conclusion: Pretreatment plasma levels of VEGF are a useful marker for predicting disease control by chemotherapy.</style></abstract></record></records></xml>